Status:

COMPLETED

Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer

Lead Sponsor:

Centre Antoine Lacassagne

Conditions:

Lung Cancer

Eligibility:

All Genders

18-120 years

Phase:

NA

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Stereot...

Detailed Description

OBJECTIVES: Primary * Evaluate the maximum tolerated dose of stereotactic radiosurgery in patients with locally advanced non-small cell lung cancer undergoing concurrent chemoradiotherapy. (Phase I)...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed non-small cell lung cancer
  • Locally advanced disease
  • No metastatic disease
  • Unable to undergo surgery after concurrent chemoradiotherapy
  • Must have 1-3 tumor target masses \< 5 cm in greatest diameter and separated by ≥ 2 cm after concurrent chemoradiotherapy
  • PATIENT CHARACTERISTICS:
  • WHO performance status 0-2
  • Platelet count \> 100,000/mm³
  • Hemoglobin \> 9 g/dL
  • Neutrophil \> 1.0 x 10\^9/L
  • FEV\_1 \> 30% of vital capacity
  • Vital capacity \> 25% of predicted value
  • DLCO \> 25% of predicted value
  • LVEF ≥ 35%
  • PT \> 80
  • aPTT \> 35 sec
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 6 months after completion of study treatment
  • Not under guardianship
  • No dyspnea related to NYHA class III-IV heart failure
  • No indirect signs of pulmonary arterial hypertension (pulmonary arterial systolic BP \> 45 mm Hg)
  • No pulmonary acceleration time \< 100 ms
  • No contraindication to fiducial insertion
  • No geographical, social, or psychological conditions that would interfere with medical follow-up
  • PRIOR CONCURRENT THERAPY:
  • Docetaxel and platinum-based drugs with concurrent irradiation allowed
  • No prior surgery or surgery after the first phase of treatment with concurrent chemoradiotherapy
  • No prior irradiation to lung
  • No concurrent participation in another study trial

Exclusion

    Key Trial Info

    Start Date :

    April 24 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 17 2016

    Estimated Enrollment :

    35 Patients enrolled

    Trial Details

    Trial ID

    NCT00945451

    Start Date

    April 24 2009

    End Date

    November 17 2016

    Last Update

    September 16 2019

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Centre Antoine Lacassagne

    Nice, France, 06189